The Role of Donor Gamma-Glutamyl Transferase as a Risk Factor for Early Graft Function after Liver Transplantation
-
Published:2023-07-18
Issue:14
Volume:12
Page:4744
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Lai Quirino1ORCID, Melandro Fabio1, Manzia Tommaso2ORCID, Spoletini Gabriele3ORCID, Crovetto Anna4ORCID, Gallo Gaetano1, Hassan Redan1ORCID, Mennini Gianluca1, Angelico Roberta2ORCID, Avolio Alfonso3ORCID, Berrevoet Frederik4ORCID, Abreu de Carvalho Luís4, Agnes Salvatore3, Tisone Giuseppe2, Rossi Massimo1
Affiliation:
1. General Surgery and Organ Transplantation Unit, Department of General and Specialty Surgery, Sapienza University of Rome, AOU Policlinico Umbertot I of Rome, 00185 Rome, Italy 2. HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00173 Rome, Italy 3. General Surgery and Liver Transplantation, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy 4. Department of General and HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Ghent, Belgium
Abstract
Background: Growing interest has been recently reported in the potential detrimental role of donor gamma-glutamyl transferase (GGT) peak at the time of organ procurement regarding the risk of poor outcomes after liver transplantation (LT). However, the literature on this topic is scarce and controversial data exist on the mechanisms justifying such a correlation. This study aims to demonstrate the adverse effect of donor GGT in a large European LT cohort regarding 90-day post-transplant graft loss. Methods: This is a retrospective international study investigating 1335 adult patients receiving a first LT from January 2004 to September 2018 in four collaborative European centers. Results: Two different multivariable logistic regression models were constructed to evaluate the risk factors for 90-day post-transplant graft loss, introducing donor GGT as a continuous or dichotomous variable. In both models, donor GGT showed an independent role as a predictor of graft loss. In detail, the log-transformed continuous donor GGT value showed an odds ratio of 1.46 (95% CI = 1.03–2.07; p = 0.03). When the donor GGT peak value was dichotomized using a cut-off of 160 IU/L, the odds ratio was 1.90 (95% CI = 1.20–3.02; p = 0.006). When the graft-loss rates were investigated, significantly higher rates were reported in LT cases with donor GGT ≥160 IU/L. In detail, 90-day graft-loss rates were 23.2% vs. 13.9% in patients with high vs. low donor GGT, respectively (log-rank p = 0.004). Donor GGT was also added to scores conventionally used to predict outcomes (i.e., MELD, D-MELD, DRI, and BAR scores). In all cases, when the score was combined with the donor GGT, an improvement in the model accuracy was observed. Conclusions: Donor GGT could represent a valuable marker for evaluating graft quality at transplantation. Donor GGT should be implemented in scores aimed at predicting post-transplant clinical outcomes. The exact mechanisms correlating GGT and poor LT outcomes should be better clarified and need prospective studies focused on this topic.
Reference26 articles.
1. 2018 Annual Report of the European Liver Transplant Registry (ELTR)-50-year evolution of liver transplantation;Adam;Transpl. Int.,2018 2. Hepatocellular cancer selection systems and liver transplantation: From the tower of babel to an ideal comprehensive score;Lerut;Updat. Surg.,2021 3. Quaresima, S., Melandro, F., Giovanardi, F., Shah, K., De Peppo, V., Mennini, G., Ghinolfi, D., Limkemann, A., Pawlik, T.M., and Lai, Q. (2023). New Insights in the Setting of Transplant Oncology. Medicina, 59. 4. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy;Ravaioli;J. Hepatol.,2022 5. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant;Lai;JAMA Surg.,2021
|
|